These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 7536433

  • 1. The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Anderson H, Bleehen NM, Girling DJ, Lallemand G, Machin D, Stephens RJ.
    Eur J Cancer; 1995; 31A(2):152-6. PubMed ID: 7536433
    [Abstract] [Full Text] [Related]

  • 2. Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working Party.
    Thatcher N, Clark PI, Smith DB, Anderson H, Girling DJ, Machin D, Stephens RJ, Lallemand G, Jenkins B.
    Clin Oncol (R Coll Radiol); 1995; 7(5):293-9. PubMed ID: 8580054
    [Abstract] [Full Text] [Related]

  • 3. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party.
    Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ.
    J Clin Oncol; 2000 Jan; 18(2):395-404. PubMed ID: 10637255
    [Abstract] [Full Text] [Related]

  • 4. High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.
    Ardizzoni A, Venturini M, Crinò L, Sertoli MR, Bruzzi P, Pennucci MC, Mariani GL, Garrone O, Bracarda S, Rosso R.
    Eur J Cancer; 1993 Jan; 29A(5):687-92. PubMed ID: 8385970
    [Abstract] [Full Text] [Related]

  • 5. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G.
    N Engl J Med; 1991 Jul 18; 325(3):164-70. PubMed ID: 1711156
    [Abstract] [Full Text] [Related]

  • 6. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma.
    Hamm J, Schiller JH, Cuffie C, Oken M, Fisher RI, Shepherd F, Kaiser G.
    J Clin Oncol; 1994 Dec 18; 12(12):2667-76. PubMed ID: 7989942
    [Abstract] [Full Text] [Related]

  • 7. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN, de Boo TM, Smit HJ, Biesma B, Wilschut FA, Cheragwandi SA, Termeer A, Hensing CA, Akkermans J, Adang EM, Bootsma GP, Tjan-Heijnen VC.
    J Clin Oncol; 2005 Nov 01; 23(31):7974-84. PubMed ID: 16258098
    [Abstract] [Full Text] [Related]

  • 8. Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
    Ardizzoni A, Tjan-Heijnen VC, Postmus PE, Buchholz E, Biesma B, Karnicka-Mlodkowska H, Dziadziuszko R, Burghouts J, Van Meerbeeck JP, Gans S, Legrand C, Debruyne C, Giaccone G, Manegold C, European Organization for Research and Treatment of Cancer-Lung Cancer Group.
    J Clin Oncol; 2002 Oct 01; 20(19):3947-55. PubMed ID: 12351591
    [Abstract] [Full Text] [Related]

  • 9. Cost effectiveness of increasing the dose intensity of chemotherapy with granulocyte colony-stimulating factor in small-cell lung cancer: based on data from the Medical Research Council LU19 trial.
    Bojke L, Sculpher M, Stephens R, Qian W, Thatcher N, Girling D.
    Pharmacoeconomics; 2006 Oct 01; 24(5):443-52. PubMed ID: 16706570
    [Abstract] [Full Text] [Related]

  • 10. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
    Woll PJ, Hodgetts J, Lomax L, Bildet F, Cour-Chabernaud V, Thatcher N.
    J Clin Oncol; 1995 Mar 01; 13(3):652-9. PubMed ID: 7533825
    [Abstract] [Full Text] [Related]

  • 11. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun 01; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 12. Phase I study of simultaneous dose escalation and schedule acceleration of cyclophosphamide-doxorubicin-etoposide using granulocyte colony-stimulating factor with or without antimicrobial prophylaxis in patients with small-cell lung cancer.
    Ardizzoni A, Pennucci MC, Danova M, Viscoli C, Mariani GL, Giorgi G, Venturini M, Mereu C, Scolaro T, Rosso R.
    Br J Cancer; 1996 Oct 01; 74(7):1141-7. PubMed ID: 8855989
    [Abstract] [Full Text] [Related]

  • 13. Dose intensity phase I/II trial with carboplatin, ifosfamide, etoposide and vincristine combined with filgrastim in patients with small-cell lung cancer.
    Hanauske AR, Korfel A, Perker M, Heinrich B, Schwab G, Graf M, Depenbrock H, Höffken G, Kreuser ED, Thiel E, Zwingers T, Berdel WE.
    Oncology; 1997 Oct 01; 54(5):363-70. PubMed ID: 9260596
    [Abstract] [Full Text] [Related]

  • 14. The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer.
    Trillet-Lenoir V, Soler P, Arpin D, Bohas C, Riou R, Court-Fortune I, Ecochard D, Perol M, Cordier JF.
    Lung Cancer; 1996 Jun 01; 14(2-3):331-41. PubMed ID: 8794414
    [Abstract] [Full Text] [Related]

  • 15. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia.
    Michel G, Landman-Parker J, Auclerc MF, Mathey C, Leblanc T, Legall E, Bordigoni P, Lamagnere JP, Demeocq F, Perel Y, Auvrignon A, Berthou C, Bauduer F, Pautard B, Schneider P, Schaison G, Leverger G, Baruchel A.
    J Clin Oncol; 2000 Apr 01; 18(7):1517-24. PubMed ID: 10735900
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human granulocyte colony-stimulating factor infusion and/or autologous peripheral blood stem cell transplantation as a rescue for sequential high-dose combination chemotherapy: a preliminary report.
    Chau WK, Lin CK, Chow MP, Wang SY, Liu JM, Ho CH, Chiu CF, Hsu HC, Tan TD, Chan WK.
    Zhonghua Yi Xue Za Zhi (Taipei); 1994 Nov 01; 54(5):312-20. PubMed ID: 7530591
    [Abstract] [Full Text] [Related]

  • 17. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854.
    Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA, Canellos GP, Robert M, Johnson JL, Peterson BA.
    Cancer; 2001 Jul 15; 92(2):207-17. PubMed ID: 11466671
    [Abstract] [Full Text] [Related]

  • 18. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 15; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 19. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D.
    J Clin Oncol; 1997 May 15; 15(5):1722-9. PubMed ID: 9164178
    [Abstract] [Full Text] [Related]

  • 20. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
    Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M.
    Cancer Chemother Pharmacol; 2007 Jun 15; 60(1):1-6. PubMed ID: 17393168
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.